L&G Pharma Breakthrough UCITS ETF (LON:BIGT)
London · Delayed Price · Currency is GBP · Price in GBX 1,036.00
+1.00 (0.10%)
Apr 2, 2026, 4:28 PM GMT
27.57% (1Y)
| Assets | 14.18M |
| Expense Ratio | 0.49% |
| PE Ratio | 17.88 |
| Dividend (ttm) | n/a |
| Dividend Yield | n/a |
| Ex-Dividend Date | n/a |
| Payout Frequency | n/a |
| Payout Ratio | n/a |
| 1-Year Return | +27.57% |
| Volume | 4,441 |
| Open | 1,027.72 |
| Previous Close | 1,035.00 |
| Day's Range | 1,027.00 - 1,037.93 |
| 52-Week Low | 705.20 |
| 52-Week High | 1,057.60 |
| Beta | 0.47 |
| Holdings | 42 |
| Inception Date | Jan 23, 2018 |
About BIGT
The L&G Pharma Breakthrough UCITS ETF (the "ETF") aims to track the performance of the Solactive Pharma Breakthrough Value Index (the "Index").
Asset Class Equity
Category Health Care
Stock Exchange London Stock Exchange
Ticker Symbol BIGT
Provider L&G
Index Tracked Solactive Pharma Breakthrough Value Index
Performance
BIGT had a total return of 27.57% in the past year, including dividends. Since the fund's inception, the average annual return has been 4.49%.
Top 10 Holdings
30.62% of assets| Name | Symbol | Weight |
|---|---|---|
| Sarepta Therapeutics, Inc. | SRPT | 3.40% |
| United Therapeutics Corporation | UTHR | 3.37% |
| InnoCare Pharma Ltd | INCPF | 3.15% |
| BioCryst Pharmaceuticals, Inc. | BCRX | 3.09% |
| Kyowa Kirin Co., Ltd. | 4151 | 3.08% |
| Agios Pharmaceuticals, Inc. | AGIO | 2.96% |
| Pharma Mar, S.A. | PHM | 2.92% |
| BridgeBio Pharma, Inc. | BBIO | 2.91% |
| Pharming Group N.V. | PHARM | 2.88% |
| PTC Therapeutics, Inc. | PTCT | 2.87% |